Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.49 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 2/20 | 0.33 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4519281 | 0.91 | HSD11B1 (0.53) | HSD11B1LIPGP2RX7HRH3SIGMAR1 | |
| SCHEMBL4510247 | 0.88 | HSD11B1 (0.47) | HSD11B1ALDH1A1KMT2A | |
| SCHEMBL4515140 | 0.85 | HSD11B1 (0.45) | HSD11B1LIPGP2RX7HRH3ALDH1A1 | |
| SCHEMBL4518301 | 0.85 | HSD11B1 (0.51) | HSD11B1LIPGP2RX7HRH3SIGMAR1 | |
| SCHEMBL13675546 | 0.85 | HSD11B1 (0.55) | HSD11B1P2RX7HRH3TP53LMNA | |
| SCHEMBL13674557 | 0.85 | HSD11B1 (0.44) | HSD11B1P2RX7ALDH1A1KMT2A | |
| SCHEMBL4516723 | 0.84 | HSD11B1 (0.51) | HSD11B1LMNAALDH1A1KMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4517646 | 0.84 | HSD11B1 (0.43) | HSD11B1P2RX7HRH3ALDH1A1KMT2A | |
| SCHEMBL4513991 | 0.81 | TP53 (0.42) | HSD11B1TP53ALDH1A1KMT2A | |
| SCHEMBL4512444 | 0.80 | HSD11B1 (0.54) | HSD11B1P2RX7SIGMAR1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| EP-1864971-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885PDE7A 1218/4885LIPG 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.